NO943625L - Monoklonale antistoffer mot interferonreseptoren med nöytraliserende aktivitet mot type-I-interferon - Google Patents

Monoklonale antistoffer mot interferonreseptoren med nöytraliserende aktivitet mot type-I-interferon

Info

Publication number
NO943625L
NO943625L NO943625A NO943625A NO943625L NO 943625 L NO943625 L NO 943625L NO 943625 A NO943625 A NO 943625A NO 943625 A NO943625 A NO 943625A NO 943625 L NO943625 L NO 943625L
Authority
NO
Norway
Prior art keywords
interferon
monoclonal antibodies
neutralizing activity
receptor
type
Prior art date
Application number
NO943625A
Other languages
English (en)
Norwegian (no)
Other versions
NO943625D0 (no
Inventor
Patrick Benoit
Francois Meyer
Debborah Maguire
Ivan Plavec
Michael G Tovey
Original Assignee
Europ De Biotechnologie Sa Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Europ De Biotechnologie Sa Lab filed Critical Europ De Biotechnologie Sa Lab
Publication of NO943625D0 publication Critical patent/NO943625D0/no
Publication of NO943625L publication Critical patent/NO943625L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO943625A 1992-03-31 1994-09-29 Monoklonale antistoffer mot interferonreseptoren med nöytraliserende aktivitet mot type-I-interferon NO943625L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92400902A EP0563487A1 (de) 1992-03-31 1992-03-31 Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
PCT/EP1993/000770 WO1993020187A1 (en) 1992-03-31 1993-03-30 Monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon

Publications (2)

Publication Number Publication Date
NO943625D0 NO943625D0 (no) 1994-09-29
NO943625L true NO943625L (no) 1994-11-11

Family

ID=8211644

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943625A NO943625L (no) 1992-03-31 1994-09-29 Monoklonale antistoffer mot interferonreseptoren med nöytraliserende aktivitet mot type-I-interferon

Country Status (18)

Country Link
US (5) US5919453A (de)
EP (3) EP0563487A1 (de)
JP (2) JP3836500B2 (de)
AT (2) ATE368055T1 (de)
AU (2) AU679909B2 (de)
BG (1) BG99141A (de)
CA (1) CA2133106C (de)
CZ (1) CZ236994A3 (de)
DE (2) DE69332997T2 (de)
DK (2) DK1329459T3 (de)
ES (2) ES2290241T3 (de)
FI (1) FI944509A7 (de)
HU (1) HUT69995A (de)
NO (1) NO943625L (de)
NZ (1) NZ251343A (de)
PT (2) PT633931E (de)
RU (1) RU94045826A (de)
WO (1) WO1993020187A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563487A1 (de) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
EP0725654A1 (de) * 1993-09-17 1996-08-14 Laboratoire Europeen De Biotechnologie S.A. Pharmazeutische zusammensetzung mit monoklonale antikoerpern gegen den interferenrezeptor, mit neutralisierender wirkung gegen typ i interferon
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6713609B1 (en) 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
CN1068524C (zh) * 1997-06-23 2001-07-18 叶庆炜 一种治疗顽症牛皮癣的药物
US6376067B1 (en) * 1998-12-21 2002-04-23 Mitsubishi Polyester Film, Llc Silicone coated film with back side slip control coating and method of controlling slip of such film
GB0001712D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
AU2007202840B2 (en) * 2001-01-09 2011-07-28 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
AU2002246955B2 (en) * 2001-01-09 2007-03-22 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
AU2007203559B2 (en) * 2003-04-23 2010-09-02 E. R. Squibb & Sons, L.L.C. Compositions and methods for the therapy of inflammatory bowel disease
US7619070B2 (en) * 2003-04-23 2009-11-17 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
CA2522957C (en) 2003-04-23 2013-10-22 Medarex, Inc. Compositions and methods for the therapy of inflammatory bowel disease
KR101151477B1 (ko) 2003-12-10 2012-06-22 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
WO2005118647A2 (en) * 2004-05-18 2005-12-15 Genentech, Inc. M13 virus major coat protein variants for c-terminal and bi-terminal display of a heterologous protein
JP5160887B2 (ja) 2004-06-21 2013-03-13 メダレックス インコーポレイテッド インターフェロンアルファレセプター１抗体及びその使用法
BRPI0516470A (pt) * 2004-10-07 2008-09-09 Universitot Zuerich uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
RU2431638C2 (ru) * 2005-02-10 2011-10-20 Бэйлор Рисерч Инститьют Моноклональные антитела против интерферона-альфа и способы применения
US20070081995A1 (en) * 2005-06-22 2007-04-12 Genentech, Inc. Methods and compositions for targeting IFNAR2
CN101678100A (zh) 2006-12-06 2010-03-24 米迪缪尼有限公司 治疗系统性红斑狼疮的方法
US8685400B2 (en) 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
EP2250279B1 (de) 2008-02-08 2016-04-13 MedImmune, LLC Anti-ifnar1-antikörper mit reduzierter fc-ligandenaffinität
AU2009245792B2 (en) 2008-05-07 2012-11-01 Coimmune, Inc. Humanized antibodies against human interferon-alpha
NZ602219A (en) * 2010-03-01 2014-10-31 Alexion Pharma Inc Methods and compositions for treating degos’ disease
WO2013134146A1 (en) * 2012-03-07 2013-09-12 The Regents Of The University Of California Methods and compositions for treating viral infections by blocking type i interferon activity
JP7308034B2 (ja) 2016-07-01 2023-07-13 リゾルブ セラピューティクス， エルエルシー 最適化二重ヌクレアーゼ融合物および方法
WO2018010140A1 (zh) * 2016-07-14 2018-01-18 中国科学院生物物理研究所 I型干扰素受体抗体及其用途
WO2019040674A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc SOLUBLE INTERFERON RECEPTORS AND USES THEREOF
US20220144957A1 (en) * 2019-01-31 2022-05-12 Immunecent Biotechnology, Inc. Novel anti-ifnar1 antibodies
CN120463762A (zh) 2021-08-26 2025-08-12 映恩生物科技(上海)有限公司 一种甾体化合物及其缀合物
CN115028730B (zh) * 2022-05-17 2022-11-08 诺赛联合(北京)生物医学科技有限公司 一种成体干细胞衍生的类器官制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953132A (en) 1955-10-27 1960-09-20 Baxter Laboratories Inc Parenteral solution equipment
US3066671A (en) 1959-10-27 1962-12-04 Milton J Cohen Disposable additive container
US3608550A (en) 1969-05-07 1971-09-28 Becton Dickinson Co Transfer needle assembly
BE791340A (fr) 1972-01-06 1973-03-01 Becton Dickinson Co Nouveaux procede et appareil de prelevement de culture et d'identification de micro-organismes des humeurs
US4024857A (en) 1974-12-23 1977-05-24 Becton, Dickinson And Company Micro blood collection device
US4300404A (en) 1977-12-01 1981-11-17 Becton, Dickinson And Company Liquid specimen container
US4116066A (en) 1977-12-12 1978-09-26 Becton, Dickinson And Company Specimen sampler cup
US5516515A (en) * 1986-02-05 1996-05-14 Interferon Sciences, Inc. Separation of alpha interferon receptor proteins and antibodies therefor
IL88377A (en) * 1988-11-14 1996-09-12 Yeda Res & Dev Cloning and expression of a protein which modulates cellular response to type I interferon
FR2653445B1 (fr) * 1989-10-20 1994-07-29 Centre Nat Rech Scient Fragment d'adnc codant pour le gene du recepteur de l'interferon alpha et procede de preparation d'une proteine correspondante.
US5889151A (en) * 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
FR2657881A1 (fr) * 1990-02-05 1991-08-09 Europ Biotechnologie Lab Nouveaux polypeptides hydrosolubles, sequences d'adn, nouvelles cellules, procede de preparation, applications et compositions renfermant lesdits polypeptides.
IL99232A0 (en) * 1990-08-20 1992-07-15 Univ Columbia Methods for producing rna viruses from cdna
CA2585487A1 (fr) * 1991-04-17 1992-10-29 Medarex Inc. Polypeptides hydrosolubles ayant une haute affinite pour les interferons .alpha. et .beta.
EP0563487A1 (de) 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
DE69332485T2 (de) * 1992-08-11 2003-11-13 The President And Fellows Of Harvard College, Cambridge Immunmodulierende peptide
DE69322289T2 (de) * 1992-12-29 1999-05-20 Genentech, Inc., South San Francisco, Calif. Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
ATE227133T1 (de) * 1994-03-07 2002-11-15 Imperial College Verwendung von interferon-alpha 8 subtype zur herstellung von medikamenten zur behandlung von viralinfektionen der leber
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor

Also Published As

Publication number Publication date
US20080226647A1 (en) 2008-09-18
EP1329459A2 (de) 2003-07-23
JP3836500B2 (ja) 2006-10-25
FI944509L (fi) 1994-11-29
EP0633931B1 (de) 2003-05-21
DK0633931T3 (da) 2003-09-15
ES2290241T3 (es) 2008-02-16
DK1329459T3 (da) 2007-11-26
DE69334158T2 (de) 2008-04-10
HUT69995A (en) 1995-09-28
NO943625D0 (no) 1994-09-29
AU2349697A (en) 1997-07-24
WO1993020187A1 (en) 1993-10-14
EP0563487A1 (de) 1993-10-06
CA2133106A1 (en) 1993-10-14
BG99141A (bg) 1995-07-28
US5919453A (en) 1999-07-06
ATE241008T1 (de) 2003-06-15
RU94045826A (ru) 1996-11-10
US20040191840A1 (en) 2004-09-30
US7179465B2 (en) 2007-02-20
US20070128701A1 (en) 2007-06-07
FI944509A7 (fi) 1994-11-29
US6787634B2 (en) 2004-09-07
JPH07505526A (ja) 1995-06-22
JP2006089494A (ja) 2006-04-06
FI944509A0 (fi) 1994-09-29
US20020055492A1 (en) 2002-05-09
CA2133106C (en) 2009-06-30
ES2199941T3 (es) 2004-03-01
AU3890793A (en) 1993-11-08
PT1329459E (pt) 2007-11-07
HU9402823D0 (en) 1995-01-30
DE69332997T2 (de) 2004-05-19
EP1329459A3 (de) 2003-09-10
NZ251343A (en) 1997-07-27
DE69332997D1 (de) 2003-06-26
EP0633931A1 (de) 1995-01-18
PT633931E (pt) 2003-09-30
EP1329459B1 (de) 2007-07-25
DE69334158D1 (de) 2007-09-06
AU706473B2 (en) 1999-06-17
US7465451B2 (en) 2008-12-16
CZ236994A3 (en) 1995-02-15
ATE368055T1 (de) 2007-08-15
AU679909B2 (en) 1997-07-17

Similar Documents

Publication Publication Date Title
NO943625L (no) Monoklonale antistoffer mot interferonreseptoren med nöytraliserende aktivitet mot type-I-interferon
Allaway et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates
CA2203182A1 (en) Remedy for diseases caused by il-6 production
ATE412430T1 (de) Monoklonale antikörper die ligandbindung an den cd22-rezeptor in reifen b-zellen unterbinden.
DE69333348D1 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten
TR199901710T2 (xx) IL-8 resept�r antagonistleri.
ES2111524T3 (es) Peptidos de eritropoyetina (epo) y anticuerpos dirigidos contra ellos.
EP0675904A4 (de) Humane neutralisierende monoklonale antikörper gegen den die immunschwäche auslösenden virus aus mensch.
DK0461177T3 (da) Humant intra-acrosomalt spermantigen til anvendelse i en svangerskabsforebyggende vaccine
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
DE69434499D1 (de) Monoklonale Antikörper und Fv gegen das CD2 Antigen
ATE204480T1 (de) Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon
ATE386805T1 (de) Verwendungen eines borreliaziden epitops des aussermembranproteins c von borrelia burgdorferi (ospc) als impstoff
ES2109242T3 (es) Anticuerpos monoclonales contra inmunoglobulina e humana.
DE69737815D1 (de) G-protein gekoppelter rezeptor mit vergrösserter, extrazellulärer domäne
TR199901761T2 (xx) IL-8 resept�r antagonistleri.
SE9201281D0 (sv) New human monoclonal antibodies, and a method for preparation thereof
CA2308007A1 (en) Enhancer for antibody to lymphocytic tumors
TR27329A (tr) Yeni metazoan parazit antigenler, bunlari kodlayan nükleik asidler.
DE69333416D1 (de) Immunologisches Verfahren für die Detektion von Pferde-Herpesvirus Typ 1 und 4 glycoprotein G Antikörper
FR2646607B1 (fr) Anticorps monoclonaux anti-b2 microglobuline
UA28690A (uk) Спосіб діагностики інфекційного ендокардиту стафілококової етіології
JPH0665099A (ja) エイズ関連医薬品組成物